Azlocillin (CAS 37091-66-0)

Azlocillin, a semisynthetic penicillin derivative, has been extensively studied in scientific research for its potent antimicrobial properties and its mechanism of action against bacterial pathogens. It functions by inhibiting bacterial cell wall synthesis through binding irreversibly to penicillin-binding proteins (PBPs), particularly PBP-1a and PBP-1b, which are essential enzymes involved in peptidoglycan cross-linking. This action disrupts the integrity of the bacterial cell wall, leading to cell lysis and ultimately bacterial death. Research on azlocillin has focused on elucidating its spectrum of activity against a wide range of Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa, Enterobacter species, and Proteus mirabilis, among others. Moreover, investigations into the pharmacokinetic properties of azlocillin have been conducted to optimize dosing regimens and assess its bioavailability, distribution, metabolism, and excretion in various biological systems. Additionally, azlocillin has been utilized as a valuable tool in microbiological research to explore bacterial resistance mechanisms, characterize structure-activity relationships of β-lactam antibiotics, and develop strategies to combat antimicrobial resistance. Ongoing research endeavors continue to delve into the pharmacological and microbiological aspects of azlocillin, aiming to expand its utility in the fight against infectious diseases and address emerging challenges posed by antibiotic resistance.